Format

Send to

Choose Destination
Brachytherapy. 2014 Nov-Dec;13(6):554-61. doi: 10.1016/j.brachy.2014.06.004. Epub 2014 Jul 20.

Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer.

Author information

1
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: Larfok@rm.dk.
2
Department of Gynaecology, Aarhus University Hospital, Aarhus, Denmark.
3
Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
4
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
5
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
6
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Abstract

PURPOSE:

To evaluate clinical outcome and feasibility of a four-dimensional image-guided adaptive brachytherapy concept in patients with locally recurrent endometrial cancer.

METHODS AND MATERIALS:

Forty-three patients with locally recurrent endometrial cancer were included. Treatment consisted of conformal external beam radiotherapy followed by a boost using pulsed-dose-rate brachytherapy (BT). Large tumors were treated with MRI-guided interstitial BT. Small tumors were treated with CT-guided intracavitary BT. The planning aim (total external beam radiotherapy and BT) for high-risk clinical target volume was D90 > 80 Gy, whereas constraints for organs at risk were D2cc ≤ 90 Gy for bladder and D2cc ≤ 70 Gy for rectum, sigmoid, and bowel in terms of equivalent dose in 2 Gy fractions.

RESULTS:

Median high-risk clinical target volume was 18 cm(3) (range, 0-91). D90 was 82 Gy (range, 77-88). D2cc to bladder, rectum, and sigmoid were 67 Gy (range, 50-81), 67 Gy (range, 51-77), and 55 Gy (range, 44-68), respectively. Median followup was 30 months (6-88). Two-year local control rate was 92% (standard error [SE], 5). Disease-free survival rate and overall survival rate was 59% (SE, 8) and 78% (SE, 7), respectively. Patients with low- to intermediate-risk for recurrence had a 2-year disease-free survival rate of 72% (SE, 9) compared with 42% (SE, 12) in patients with high risk for recurrence (p = 0.04). Late morbidity Grade 3 was recorded in 5 (12%) patients.

CONCLUSIONS:

Four-dimensional image-guided adaptive brachytherapy is feasible in locally recurrent endometrial cancer. Local control rate is good. Systemic control remains a problem in patients with high risk for recurrence.

KEYWORDS:

Image-guided adaptive brachytherapy; Recurrent endometrial cancer

PMID:
25056640
DOI:
10.1016/j.brachy.2014.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center